Quanticate is a leading global data focused clinical research organisation (CRO) primarily focused on the management, analysis and reporting of data from clinical trials and post-marketing surveillance. As experts in clinical data, Quanticate provides high quality teams that offer efficient outsourcing solutions for: • Clinical Data Management • Biostatistics • SAS Programming • Data quality oversight via Centralized Statistical Monitoring • Medical writing • Pharmacovigilance Quanticate can offer study level support, functional service provision (FSP), strategic full data-services solutions or technical consultancy to meet the needs of pharmaceutical, biotechnology and device companies across the globe. Quanticate has become the supplier of choice for many companies from top tier pharmaceutical giants through to niche biotechnology and device companies.
Quanticate is seeking a skilled Statistical Programmer I to join their clinical research team. The role involves contributing to statistical and programming tasks in clinical trial reporting, including data design, analysis planning, and report generation. Quanticate is a leading data-focused CRO specializing in assisting global pharmaceutical companies with their complex clinical trials.
Quanticate is a leading global data focused clinical research organisation (CRO) primarily focused on the management, analysis and reporting of data from clinical trials and post-marketing surveillance. As experts in clinical data, Quanticate provides high quality teams that offer efficient outsourcing solutions for: • Clinical Data Management • Biostatistics • SAS Programming • Data quality oversight via Centralized Statistical Monitoring • Medical writing • Pharmacovigilance Quanticate can offer study level support, functional service provision (FSP), strategic full data-services solutions or technical consultancy to meet the needs of pharmaceutical, biotechnology and device companies across the globe. Quanticate has become the supplier of choice for many companies from top tier pharmaceutical giants through to niche biotechnology and device companies.